Inventor · disambiguated record
Bob D. Brown
Also filed as: BROWN BOB · BROWN BOB D · BROWN BOB DALE
95 granted patents·56 pending applications·1,487 citations·filing 1994–2025
99Inventor score
Files withDICERNA PHARMACEUTICALS INC104GENTA INC7PROMEGA BIOSCIENCES INC6BROWN BOB D5BROWN BOB DALE5
Top patents by PatentIndex Score
151 records- 0199US8927705B2Single stranded extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2012·Granted Jan 6, 2015·83 cites·46 claims
- 0298US8349809B2Single stranded extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2010·Granted Jan 8, 2013·162 cites·102 claims
- 0396US10370655B2Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2016·Granted Aug 6, 2019·14 cites·22 claims
- 0496US10144725B2Amine cationic lipids and uses thereofDICERNA PHARMACEUTICALS INC·Filed 2017·Granted Dec 4, 2018·21 cites·25 claims
- 0596US9458457B2Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2014·Granted Oct 4, 2016·19 cites·52 claims
- 0696US8513207B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionBROWN BOB DALE·Filed 2009·Granted Aug 20, 2013·219 cites·93 claims
- 0795US11359198B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2021·Granted Jun 14, 2022·2 cites·23 claims
- 0894US10870849B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2014·Granted Dec 22, 2020·7 cites·63 claims
- 0994US10131912B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2014·Granted Nov 20, 2018·15 cites·8 claims
- 1094US8372816B2Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2010·Granted Feb 12, 2013·12 cites·57 claims
- 1194US6251939B1Carbamate-based cationic lipidsPROMEGA BIOSCIENCES INC·Filed 1996·Granted Jun 26, 2001·66 cites·13 claims
- 1293US12077756B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2022·Granted Sep 3, 2024·1 cites·22 claims
- 1393US11661604B2Methods and compositions for inhibiting expression of LDHADICERNA PHARMACEUTICALS INC·Filed 2020·Granted May 30, 2023·3 cites·20 claims
- 1493US10036017B2Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2016·Granted Jul 31, 2018·5 cites·24 claims
- 1593US9701966B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2014·Granted Jul 11, 2017·12 cites·68 claims
- 1693US6638529B2Amide-based cationic lipidsPROMEGA BIOSCIENCES INC·Filed 2002·Granted Oct 28, 2003·45 cites·77 claims
- 1793US6028188ASynthetic oligomers having chirally pure phosphonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkagesGENTA INC·Filed 1994·Granted Feb 22, 2000·251 cites·23 claims
- 1892US11597929B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2021·Granted Mar 7, 2023·1 cites·20 claims
- 1992US10837013B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2014·Granted Nov 17, 2020·5 cites·63 claims
- 2092US10351854B2Therapeutic inhibition of lactate dehydrogenase and agents thereforDICERNA PHARMACEUTICALS INC·Filed 2015·Granted Jul 16, 2019·9 cites·34 claims
- 2192US10150965B2Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2014·Granted Dec 11, 2018·6 cites·24 claims
- 2292US9828606B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2017·Granted Nov 28, 2017·7 cites·38 claims
- 2392US8815825B2Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2012·Granted Aug 26, 2014·12 cites·45 claims
- 2492US6172049B1Phosphonic acid-based cationic lipidsPROMEGA BIOSCIENCES INC·Filed 1999·Granted Jan 9, 2001·64 cites·35 claims
- 2591US11414664B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2021·Granted Aug 16, 2022·1 cites·20 claims
- 2691US11408003B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2021·Granted Aug 9, 2022·1 cites·23 claims
- 2791US11060093B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2019·Granted Jul 13, 2021·2 cites·20 claims
- 2891US10752899B2Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2017·Granted Aug 25, 2020·3 cites·31 claims
- 2991US10676742B2Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2018·Granted Jun 9, 2020·3 cites·30 claims
- 3091US9200284B2Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2013·Granted Dec 1, 2015·5 cites·53 claims
- 3190US11053502B1Therapeutic inhibition of lactate dehydrogenase and agents thereforDICERNA PHARMACEUTICALS INC·Filed 2020·Granted Jul 6, 2021·2 cites·30 claims
- 3290US10738311B2Therapeutic inhibition of lactate dehydrogenase and agents thereforDICERNA PHARMACEUTICALS INC·Filed 2019·Granted Aug 11, 2020·3 cites·39 claims
- 3389US11773390B2Methods and compositions for the specific inhibition of Complement Component 5(C5) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2020·Granted Oct 3, 2023·1 cites·20 claims
- 3488US11634713B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2020·Granted Apr 25, 2023·1 cites·32 claims
- 3588US10954517B2Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2018·Granted Mar 23, 2021·2 cites·20 claims
- 3688US9809819B2Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2014·Granted Nov 7, 2017·6 cites·26 claims
- 3788US8927515B2Methods and compositions for the specific inhibition of androgen receptor by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2012·Granted Jan 6, 2015·9 cites·42 claims
- 3888US5877220AAmide-based oligomeric cationic lipidsGENTA INC·Filed 1997·Granted Mar 2, 1999·71 cites·37 claims
- 3987US12252691B2Compositions and methods for inhibiting LPA expressionDICERNA PHARMACEUTICALS INC·Filed 2024·Granted Mar 18, 2025·0 cites·4 claims
- 4087US11447777B2Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2020·Granted Sep 20, 2022·1 cites·27 claims
- 4187US10435692B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2017·Granted Oct 8, 2019·3 cites·20 claims
- 4286US9732347B2Methods and compositions for the specific inhibition of androgen receptor by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2014·Granted Aug 15, 2017·6 cites·38 claims
- 4386US6034135ADimeric cationic lipidsPROMEGA BIOSCIENCES INC·Filed 1997·Granted Mar 7, 2000·64 cites·41 claims
- 4486US6020526AAmide-based cationic lipidsGENTA INC·Filed 1996·Granted Feb 1, 2000·73 cites·11 claims
- 4585US10689647B2Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2016·Granted Jun 23, 2020·2 cites·32 claims
- 4685US10612023B2Methods and compositions for the specific inhibition of β-catenin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2018·Granted Apr 7, 2020·1 cites·21 claims
- 4785US10487330B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2019·Granted Nov 26, 2019·2 cites·30 claims
- 4885US10465195B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2019·Granted Nov 5, 2019·2 cites·28 claims
- 4985US9217146B2Phase changing formulations of nucleic acid payloadsDICERNA PHARMACEUTICALS INC·Filed 2013·Granted Dec 22, 2015·4 cites·20 claims
- 5085US6670393B2Carbamate-based cationic lipidsPROMEGA BIOSCIENCES INC·Filed 2001·Granted Dec 30, 2003·19 cites·4 claims
Showing the top 50 of 151 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Bob D. Brown files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →